Literature DB >> 21536589

FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3.

Julieta Araujo1, Peter Breuer, Susanne Dieringer, Sybille Krauss, Stephanie Dorn, Katrin Zimmermann, Alexander Pfeifer, Thomas Klockgether, Ullrich Wuellner, Bernd O Evert.   

Abstract

Ataxin-3 (ATXN3), the disease protein in spinocerebellar ataxia type 3 (SCA3), binds to target gene promoters and modulates transcription by interaction with transcriptional regulators. Here, we show that ATXN3 interacts with the forkhead box O (FOXO) transcription factor FOXO4 and activates the FOXO4-dependent transcription of the manganese superoxide dismutase (SOD2) gene. Upon oxidative stress, ATXN3 and FOXO4 translocate to the nucleus, concomitantly bind to the SOD2 gene promoter and increase the expression of the antioxidant enzyme SOD2. Compared with normal ATXN3, mutant ATXN3 has a reduced capability to activate the FOXO4-mediated SOD2 expression and interferes with binding of FOXO4 to the SOD2 gene promoter. These findings are consistent with a downregulation of SOD2 in pontine brain tissue and lymphoblastoid cell (LC) lines of SCA3 patients. In response to oxidative stress, LCs from SCA3 patients show a specific impairment to upregulate SOD2 expression in correlation with a significantly increased formation of reactive oxygen species and cytotoxicity. The impairment to increase the expression of SOD2 under oxidative stress conditions is associated with a significantly reduced binding of FOXO4 to the SOD2 gene promoter in SCA3-LCs. Finally and consistent with a regulatory role of ATXN3 in SOD2 expression, knockdown of endogenous ATXN3 by RNA interference represses the expression of SOD2. These findings support that ATXN3 plays an important role in regulating the FOXO4-dependent antioxidant stress response via SOD2 and suggest that a decreased antioxidative capacity and increased susceptibility towards oxidative stress contributes to neuronal cell death in SCA3.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536589     DOI: 10.1093/hmg/ddr197

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  34 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

2.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

3.  Overexpression of Cystathionine γ-Lyase Suppresses Detrimental Effects of Spinocerebellar Ataxia Type 3.

Authors:  Pauline M Snijder; Madina Baratashvili; Nicola A Grzeschik; Henri G D Leuvenink; Lucas Kuijpers; Sippie Huitema; Onno Schaap; Ben N G Giepmans; Jeroen Kuipers; Jan Lj Miljkovic; Aleksandra Mitrovic; Eelke M Bos; Csaba Szabó; Harm H Kampinga; Pascale F Dijkers; Eelke M Bos; Csaba Szabó; Harm H Kampinga; Pascale F Dijkers; Wilfred F A den Dunnen; Milos R Filipovic; Harry van Goor; Ody C M Sibon
Journal:  Mol Med       Date:  2015-10-13       Impact factor: 6.354

4.  Maternal obesity is associated with a lipotoxic placental environment.

Authors:  J Saben; F Lindsey; Y Zhong; K Thakali; T M Badger; A Andres; H Gomez-Acevedo; K Shankar
Journal:  Placenta       Date:  2014-01-11       Impact factor: 3.481

5.  CTRP7 deletion attenuates obesity-linked glucose intolerance, adipose tissue inflammation, and hepatic stress.

Authors:  Pia S Petersen; Xia Lei; Risa M Wolf; Susana Rodriguez; Stefanie Y Tan; Hannah C Little; Michael A Schweitzer; Thomas H Magnuson; Kimberley E Steele; G William Wong
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-02-21       Impact factor: 4.310

6.  Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing α-Synuclein.

Authors:  Carolina Noronha; Rita Perfeito; Mário Laço; Ullrich Wüllner; A Cristina Rego
Journal:  Neurochem Res       Date:  2017-02-25       Impact factor: 3.996

Review 7.  The expanding role for chromatin and transcription in polyglutamine disease.

Authors:  Ryan D Mohan; Susan M Abmayr; Jerry L Workman
Journal:  Curr Opin Genet Dev       Date:  2014-08-11       Impact factor: 5.578

Review 8.  Current perspective on the regulation of FOXO4 and its role in disease progression.

Authors:  Wen Liu; Yong Li; Bing Luo
Journal:  Cell Mol Life Sci       Date:  2019-09-16       Impact factor: 9.261

Review 9.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

10.  Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.

Authors:  A Matilla-Dueñas; T Ashizawa; A Brice; S Magri; K N McFarland; M Pandolfo; S M Pulst; O Riess; D C Rubinsztein; J Schmidt; T Schmidt; D R Scoles; G Stevanin; F Taroni; B R Underwood; I Sánchez
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.